A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

• Status: NOT_YET_RECRUITING
• Trial end date: 2031-11-26

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)

• Phase: PHASE1

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: BioNTech SE
• Treatments: cabozantinib; Ipilimumab; Nivolumab